海南海藥(000566.SZ):上半年預虧1.3億元-1.7億元
格隆匯7月10日丨海南海藥(000566.SZ)公佈2024年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤虧損1.3億元-1.7億元,上年同期盈利954.61萬元;扣除非經常性損益後的淨利潤虧損8,000萬元-12,000萬元,上年同期虧損9,154.88萬元;基本每股收益虧損0.1002元/股-0.131元/股;營業收入60,000萬元-85,000萬元,扣除後營業收入58,500萬元-83,500萬元。
2024年1-6月,公司歸屬於上市公司股東的淨利潤預計為虧損13,000萬元至17,000萬元。主要原因如下:
1.信用減值損失同比上升。報吿期信用減值損失預計金額約-0.27億元,較上年同期0.70億元增加約0.96億元。主要系報吿期根據最新訴訟進展情況,確認預計負債0.76億元。
2.投資收益同比下降。報吿期投資收益預計金額約-0.58億元,較上年同期-0.12億元減少約0.45億元。主要系報吿期債務重組損失0.39億元所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.